Teligent, Inc.
TLGT evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for TLGT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2021.
Tracking 1 pipeline candidate · 1 FDA decision for Teligent, Inc..
Run Teligent, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Teligent, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
14.6 months
OCF -$7M · Net income -$13M
Lead: Approved
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Governance
Frequently asked questions
What is Teligent, Inc.'s lead drug candidate?
Teligent, Inc.'s most advanced tracked candidate is flurandrenolide (Approved).
Who is the CEO of Teligent, Inc.?
Timothy B. Sawyer is the chief executive officer of Teligent, Inc. (TLGT).
What therapeutic areas does Teligent, Inc. focus on?
Teligent, Inc. develops therapies across Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.